{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:35:21Z","timestamp":1786736121471,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/jcrt.jcrt_241_19","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T05:44:58Z","timestamp":1578635098000},"page":"1561","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer"],"prefix":"10.4103","volume":"15","author":[{"given":"Ping","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.275549-1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0973-1482.275549-2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/jncimonographs\/lgv023","article-title":"International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the fifth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2013)","author":"Amoroso","year":"2015","journal-title":"J Natl Cancer Inst Monogr"},{"key":"key-10.4103\/0973-1482.275549-3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"key-10.4103\/0973-1482.275549-4","first-page":"1796","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","author":"von","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275549-5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3816\/CBC.2010.n.011","article-title":"A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil\/epirubicin\/cyclophosphamide in locally advanced breast cancer","author":"Robidoux","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"key-10.4103\/0973-1482.275549-6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clbc.2014.09.010","article-title":"The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: A multicenter clinical trial","author":"Shigematsu","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"key-10.4103\/0973-1482.275549-7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clbc.2014.12.003","article-title":"Phase II study of neoadjuvant anthracycline-based regimens combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer","author":"Tanaka","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"key-10.4103\/0973-1482.275549-8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): A randomised, phase 3 trial","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0973-1482.275549-9","doi-asserted-by":"crossref","first-page":"S730","DOI":"10.4103\/0973-1482.188292","article-title":"Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice","author":"Casanova-Martinez","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"key-10.4103\/0973-1482.275549-10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/0973-1482.181181","article-title":"Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine\/nab-paclitaxel: Results of a retrospective analysis","author":"Montes","year":"2017","journal-title":"J Cancer Res Ther"},{"key":"key-10.4103\/0973-1482.275549-11","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275549-12","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy","author":"Kuerer","year":"1999","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275549-13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18","author":"Wolmark","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"key-10.4103\/0973-1482.275549-14","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":", Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27","author":"Bear","year":"2006","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275549-15","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1200\/JCO.2004.02.122","article-title":"Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer","author":"Di\u00e9ras","year":"2004","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275549-16","first-page":"3506","article-title":"Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study","author":"von","year":"2001","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275549-17","first-page":"2676","article-title":"Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German breast group","author":"von","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275549-18","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ejca.2007.04.020","article-title":"Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: Further results from a randomised controlled trial","author":"M\u00fcller","year":"2007","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0973-1482.275549-19","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27","author":"Bear","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275549-20","first-page":"412","article-title":"Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases","author":"Kim","year":"2011","journal-title":"J Cancer Res Ther"},{"key":"key-10.4103\/0973-1482.275549-21","first-page":"665","article-title":"Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy","author":"ten","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/0973-1482.275549-22","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275549-23","doi-asserted-by":"crossref","first-page":"e23880","DOI":"10.1371\/journal.pone.0023880","article-title":"Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone","author":"Chlenski","year":"2011","journal-title":"PLoS One"},{"key":"key-10.4103\/0973-1482.275549-24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","article-title":"Impact of albumin on drug delivery \u2013 New applications on the horizon","author":"Elsadek","year":"2012","journal-title":"J Control Release"},{"key":"key-10.4103\/0973-1482.275549-25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.plefa.2004.12.003","article-title":"Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes","author":"Watkins","year":"2005","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"key-10.4103\/0973-1482.275549-26","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/0008-5472.CAN-03-2028","article-title":"Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer","author":"Jones","year":"2004","journal-title":"Cancer Res"},{"key":"key-10.4103\/0973-1482.275549-27","doi-asserted-by":"crossref","first-page":"e62451","DOI":"10.1371\/journal.pone.0062451","article-title":", Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, et al. Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: A pooled in-silico analysis","author":"Azim","year":"2013","journal-title":"PLoS One"},{"key":"key-10.4103\/0973-1482.275549-28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/annonc\/mdu487","article-title":"Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy","author":"Lindner","year":"2015","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1482.275549-29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/CAD.0b013e32830f9046","article-title":"Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status","author":"Desai","year":"2008","journal-title":"Anticancer Drugs"},{"key":"key-10.4103\/0973-1482.275549-30","first-page":"299","article-title":"Unraveling the mysteries of serum albumin-more than just a serum protein","author":"Merlot","year":"2014","journal-title":"Front Physiol"},{"key":"key-10.4103\/0973-1482.275549-31","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/JTO.0b013e318217b739","article-title":"Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer","author":"Shao","year":"2011","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:37:35Z","timestamp":1786732655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_241_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"alternative-id":["275549"],"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_241_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}